Découvrez nos professeurs et professeures!

Frédéric Pouliot

Médecin clinicien enseignant agrégé

Frédéric Pouliot
Centre de recherche sur le cancer
Centre de recherche du CHU de Québec - Université Laval
Partager la fiche :
Ce profil n’a pas encore été complété.

Contribution à la recherche

Projets de recherche

  • Surveillance of Complex Renal Cysts: The SOCRATIC study - Instituts de recherche en santé du Canada - Subvention Projet, Université de Sherbrooke, co-chercheur - 2019-10-01 au 2028-09-30
  • Towards Personalized Dosimetry-Based Radioligand Therapy of Prostate Cancer as a New Standard of Practice - Instituts de recherche en santé du Canada - Subvention Projet, co-chercheur - 2022-04-01 au 2027-03-31
  • Fonds institutionnel d'exploitation des infrastructures pour l'Université Laval - Fondation Canadienne pour l'innovation (La) - Fonds d'exploitation des infrastructures (FEI), co-chercheur - 2002-04-01 au 2025-03-31
  • Utilisation de l’imagerie moléculaire par microscopie à bioluminescence ou par tomographie par émission de positrons afin d’optimiser les stratégies thérapeutiques des patients atteints de cancers urologiques - Fonds de recherche du Québec - Santé - Chercheurs-boursiers cliniciens - Juniors 1 et 2, Seniors, chercheur principal - 2019-07-01 au 2023-06-30
  • Banque de tissus et de données médicales PROSTEP-002 (Biobanque PROSTEP-002) - CHU de Québec – Université Laval – CHUL - Développement de la recherche (FC), chercheur principal - 2021-01-01 au 2023-01-01
  • National Program on Radioligand Therapy for Prostate Cancer - Cancer de la prostate Canada, BC Cancer Agency, co-chercheur - 2018-01-01 au 2022-12-31
  • Optimiser les soins des patients atteints du cancer de la prostate résistant à la castration en utilisant une stratégie de triple traceur en imagerie moléculaire et en radiothérapieléculaire et en radiothérapie ciblée - Fonds de recherche du Québec - Santé - ONCOPOLE EMC2: Équipes multi-institutionnelles contre le cancer, Université de Sherbrooke, co-chercheur - 2018-04-01 au 2022-06-30
  • A Randomized Phase II Study of 177Lu-PSMA-617 vs Docetaxel in Patients with Metastatic Castration-Resistant Prostate Cancer and PSMA-Positive Disease - Groupe canadien des essais sur le cancer, chercheur principal - 2021-04-01 au 2022-03-31
  • Analyse fonctionnelle de l'activité androgénique totale sérique et plasmatique des hommes atteints d'un cancer de la prostate et traités par castration. - CHU de Québec – Université Laval – CHUL - Développement de la recherche (FC), chercheur principal - 2021-04-01 au 2022-03-31
  • Bourse Concert pour la vie - Fondation du CHU de Québec, co-chercheur - 2020-11-13 au 2021-11-12
  • CUASF-BCC Research Grant Program - Association canadienne d'urologie, co-chercheur - 2020-06-06 au 2021-06-05
  • Projet de recherche sur le cancer de la prostate intitulé Ironman - Fondation du CHU de Québec, chercheur principal - 2020-03-24 au 2021-03-23
  • Modeling Prostate Cancer in 30 using tissue engineering - Association canadienne d'urologie, co-chercheur - 2019-09-11 au 2020-09-10

Publications

  • A transcriptional biosensor to monitor single cancer cell therapeutic responses by bioluminescence microscopy., , Theranostics, 2022, 10.7150/thno.63744
  • Canadian Urological Association guideline: Management of small renal masses - Full-text., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2022, 10.5489/cuaj.7763
  • Canadian Urological Association guideline: Management of small renal masses - Summary of recommendations., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2022, 10.5489/cuaj.7760
  • Establishing metastatic prostate cancer quality indicators using a modified Delphi approach., , Clinical genitourinary cancer, 2022, 10.1016/j.clgc.2021.11.018
  • Subversion of infiltrating prostate macrophages to a mixed immunosuppressive tumor-associated macrophage phenotype., , Clinical and translational medicine, 2022, 10.1002/ctm2.581
  • Ultrasound Correlates Highly with Cross Sectional Imaging for Small Renal Masses in a Contemporary Cohort., , Urology, 2022, 10.1016/j.urology.2022.02.020
  • 18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) is accurate for high-grade prostate cancer bone staging when compared to bone scintigraphy., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021, 10.5489/cuaj.7107
  • 2021 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC)., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021, 10.5489/cuaj.7074
  • A multicenter, randomized, controlled phase II study: Efficacy and safety of PSMA-targeted radioligand therapy I-131-1095 (1095) plus enzalutamide (enza) in 18F-DCFPyL PSMA scan avid, metastatic castration-resistant prostate cancer (mCRPC) patients post-abiraterone (abi) progression (ARROW), , Journal of Clinical Oncology, 2021, 10.1200/JCO.2021.39.6_suppl.TPS187
  • A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with 18F-DCFPyL in Prostate Cancer Patients (OSPREY)., , The Journal of urology, 2021, 10.1097/JU.0000000000001698
  • A Phase 3 study of F-18-DCFPyL-PET/CT in Patients with Biochemically Recurrent Prostate Cancer (CONDOR): An Analysis of Disease Detection Rate and Positive Predictive Value (PPV) by Anatomic Region, , Journal of Nuclear Medicine, 2021
  • A prospective phase 2/3 study of PSMA-targeted F-18-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A sub-analysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging, , Journal of Clinical Oncology, 2021, 10.1200/JCO.2021.39.15_suppl.e17003
  • A prospective phase II/III study of PSMA-targeted 18F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A subanalysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging, , Journal of Clinical Oncology, 2021, 10.1200/JCO.2021.39.6_suppl.32
  • Achieving the "trifecta" with open versus minimally invasive partial nephrectomy., , World journal of urology, 2021, 10.1007/s00345-020-03349-y
  • Active Surveillance in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System., , Clinical genitourinary cancer, 2021, 10.1016/j.clgc.2021.05.004
  • Adrenalectomy During Radical Nephrectomy- Incidence and Oncologic Outcomes From the Canadian Kidney Cancer Information System (CKCis) -A Modern Era, Nationwide, Multicenter Cohort., , Urology, 2021, 10.1016/j.urology.2021.05.053
  • Bisphenol A Alters the Energy Metabolism of Stromal Cells and Could Promote Bladder Cancer Progression., , Cancers, 2021, 10.3390/cancers13215461
  • Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies - Executive summary., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021, 10.5489/cuaj.7357
  • Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021, 10.5489/cuaj.7355
  • CHANGES TO INITIAL RISK ASSESSMENT AND INTENDED PATIENT MANAGEMENT IN HIGH-RISK PROSTATE CANCER: AN EXPLORATORY ANALYSIS OF COHORT A FROM THE OSPREY TRIAL, , Journal of Urology, 2021
  • Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study., , Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 10.1158/1078-0432.CCR-20-4573
  • Effects of pre-operative isolation on postoperative pulmonary complications after elective surgery: an international prospective cohort study., , Anaesthesia, 2021, 10.1111/anae.15560
  • Hypothermia During Partial Nephrectomy for Patients with Renal Tumors: A Randomized Controlled Trial., , The Journal of urology, 2021, 10.1097/JU.0000000000001517
  • Identification of Abundant and Functional dodecaRNAs (doRNAs) Derived from Ribosomal RNA., , International journal of molecular sciences, 2021, 10.3390/ijms22189757
  • Impact of Time to Surgery and Surgical Delay on Oncologic Outcomes for Renal Cell Carcinoma., , The Journal of urology, 2021, 10.1097/JU.0000000000001230
  • Lymph node dissection during radical nephrectomy: A Canadian multi-institutional analysis., , Urologic oncology, 2021, 10.1016/j.urolonc.2021.02.025
  • Outcomes for patients in the pembrolizumab plus axitinib arm with advanced renal cell carcinoma (RCC) who completed two years of treatment in the phase III KEYNOTE-426 study, , Journal of Clinical Oncology, 2021, 10.1200/JCO.2021.39.6_suppl.327
  • Outcomes of Cytoreductive Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Real World Data from Canadian Centers., , European urology focus, 2021, 10.1016/j.euf.2021.10.004
  • Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426, , Journal of Clinical Oncology, 2021, 10.1200/JCO.2021.39.15_suppl.4500
  • Prognostic impact of paraneoplastic syndromes on patients with non-metastatic renal cell carcinoma undergoing surgery: Results from Canadian Kidney Cancer information system., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021, 10.5489/cuaj.6833
  • Prognostic significance of extent of venous tumor thrombus in patients with non-metastatic renal cell carcinoma: Results from a Canadian multi-institutional collaborative., , Urologic oncology, 2021, 10.1016/j.urolonc.2021.08.016
  • Proximity-dependent Mapping of the Androgen Receptor Identifies Kruppel-like Factor 4 as a Functional Partner., , Molecular & cellular proteomics : MCP, 2021, 10.1016/j.mcpro.2021.100064
  • PSMA Theranostics: Current Landscape and Future Outlook., , Cancers, 2021, 10.3390/cancers13164023
  • PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients (pts) with biochemically recurrent prostate cancer (PCa): A phase III study (CONDOR)-A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth, , Journal of Clinical Oncology, 2021, 10.1200/JCO.2021.39.6_suppl.33
  • PSMA-targeted imaging with F-18-DCFPyL-PET/CT in patients (pts) withbiochemically recurrent prostate cancer (PCa): A phase 3 study (CONDOR)-A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth, , Journal of Clinical Oncology, 2021, 10.1200/JCO.2021.39.15_suppl.5023
  • Real-world management of advanced prostate cancer: A description of management practices of community-based physicians and prostate cancer specialists., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021, 10.5489/cuaj.6779
  • Reply By Authors., , The Journal of urology, 2021, 10.1097/JU.0000000000001230.03
  • Reply by Authors., , The Journal of urology, 2021, 10.1097/JU.0000000000001946.03
  • Reply by Authors., , The Journal of urology, 2021, 10.1097/JU.0000000000001698.02
  • Results from a Canadian consensus forum of key controversial areas in the management of advanced prostate cancer: Recommendations for Canadian healthcare providers., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021, 10.5489/cuaj.7347
  • TGFβ Signaling in the Tumor Microenvironment., , Advances in experimental medicine and biology, 2021, 10.1007/978-3-030-47189-7_6
  • The increasing use of renal tumor biopsy amongst Canadian urologists: When is biopsy most utilized?, , Urologic oncology, 2021, 10.1016/j.urolonc.2021.05.026
  • The Triple-Tracer strategy against Metastatic PrOstate cancer (3TMPO) study protocol., , BJU international, 2021, 10.1111/bju.15621
  • Timing of surgery following SARS-CoV-2 infection: an international prospective cohort study., , Anaesthesia, 2021, 10.1111/anae.15458
  • ULTRASOUND CORRELATES HIGHLY WITH CROSS SECTIONAL IMAGING FOR SMALL RENAL MASSES IN A CONTEMPORARY COHORT: RESULTS FROM THE CANADIAN KIDNEY CANCER COLLABORATION, , Journal of Urology, 2021
  • Utilization and Safety of Ipilimumab Plus Nivolumab in a Real-World Cohort of Metastatic Renal Cell Carcinoma Patients., , Clinical genitourinary cancer, 2021, 10.1016/j.clgc.2021.12.003
  • A Canadian framework for managing prostate cancer during the COVID-19 pandemic: Recommendations from the Canadian Urologic Oncology Group and the Canadian Urological Association., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2020, 10.5489/cuaj.6667
  • A MULTICENTER PHASE 3 STUDY OF PSMA-TARGETED F-18-DCFPYL PET/CT IN MEN WITH BIOCHEMICALLY RECURRENT PROSTATE CANCER: RESULTS FROM THE CONDOR TRIAL, , Journal of Urology, 2020
  • A multicenter, randomized, controlled phase II study: Efficacy and safety of PSMA-targeted radioligand therapy I-131-1095 (1095) plus enzalutamide (enza) in 18F-DCFPyL PSMA scan avid, metastatic castration-resistant prostate cancer (mCRPC) patients post-abiraterone (abi) progression (ARROW), , Journal of Clinical Oncology, 2020
  • A multicenter, randomized, controlled phase II study: Efficacy and safety of PSMA-targeted radioligand therapy I-131-1095 (1095) plus enzalutamide (enza) in 18F-DCFPyL PSMA scan avid, metastatic castrationresistant prostate cancer (mCRPC) patients post-abiraterone (abi) progression (ARROW), , Journal of Clinical Oncology, 2020
  • A prospective phase II/III multicenter study of PSMA-targeted 18F-DCFPyL PET/CT imaging in patients with prostate cancer (OSPREY): A sub-analysis of regional and distant metastases detection rates at initial staging by 18F-DCFPyL PET/CT, , Journal of Clinical Oncology, 2020
  • A prospective, multisite study analyzing the percentage of urological cases that can be completely managed by telemedicine., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2020, 10.5489/cuaj.6862
  • A transcriptionally enhanced biosensor to detect and monitor biopsy-dissociated primary prostate cancer single cell drug responses by bioluminescence microscopy, , Cancer Research, 2020, 10.1158/1538-7445.Am2020-2015
  • Application of Hereditary Renal Cell Carcinoma Risk Criteria to a Large Prospective Database., , Clinical oncology (Royal College of Radiologists (Great Britain)), 2020, 10.1016/j.clon.2019.07.010
  • Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-naive and castration-sensitive prostate cancer., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2020, 10.5489/cuaj.6384
  • CLINICAL UTILITY OF PREOPERATIVE PSMA-TARGETED F-18-DCFPYL PET/CT IN MEN WITH HIGH-RISK PROSTATE CANCER: DIAGNOSTIC PERFORMANCE COMPARISONS WITH PELVIC CT OR MRI IN THE OSPREY PROSPECTIVE, MULTI-CENTER TRIAL, , Journal of Urology, 2020
  • Contribution of extragonadal steroids to the androgen receptor activity and to the castration-resistance development in recurrent prostate cancers after primary therapy, , Journal of Clinical Oncology, 2020
  • Determining generalizability of the Canadian Kidney Cancer information system (CKCis) to the entire Canadian kidney cancer population., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2020, 10.5489/cuaj.6716
  • Diagnostic Performance of PSMA-Targeted F-18-DCFPyL PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the Phase 3, Multicenter CONDOR Study, , Journal of Nuclear Medicine, 2020
  • Does renal tumor biopsies for small renal carcinoma increase the risk of upstaging on final surgery pathology report and the risk of recurrence?, , Urologic oncology, 2020, 10.1016/j.urolonc.2020.06.001
  • Extragonadal Steroids Contribute Significantly to Androgen Receptor Activity and Development of Castration Resistance in Recurrent Prostate Cancer after Primary Therapy., , The Journal of urology, 2020, 10.1097/JU.0000000000000699
  • First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated follow-up for KEYNOTE-427 cohort A, , Journal of Clinical Oncology, 2020
  • First-line pembrolizumab (pembro) monotherapy in advanced non-clear cell renal cell carcinoma (nccRCC): Updated follow-up for KEYNOTE-427 cohort B, , Journal of Clinical Oncology, 2020
  • Ga-68-PSMA-617: cellular evidence supporting later acquisition of PET images, , Journal of Nuclear Medicine, 2020
  • Ga-68-PSMA-617: from gallium production by cyclotron to clinical application, , Journal of Nuclear Medicine, 2020
  • Glucuronidation of Abiraterone and Its Pharmacologically Active Metabolites by UGT1A4, Influence of Polymorphic Variants and Their Potential as Inhibitors of Steroid Glucuronidation., , Drug metabolism and disposition: the biological fate of chemicals, 2020, 10.1124/dmd.119.088229
  • GLUT1 expression in high-risk prostate cancer: Correlation with 18F-FDG-PET/CT and clinical outcome, , Journal of Clinical Oncology, 2020
  • GLUT1 expression in high-risk prostate cancer: correlation with 18F-FDG-PET/CT and clinical outcome., , Prostate cancer and prostatic diseases, 2020, 10.1038/s41391-020-0202-x
  • HOW WELL DOES RENAL MASS SIZE MEASURED BY ULTRASOUND CORRELATE WITH MEASUREMENTS OBTAINED BY CT, MRI OR PATHOLOGY? ANALYSIS FROM THE CANADIAN KIDNEY CANCER INFORMATION SYSTEM, , Journal of Urology, 2020
  • Impact of early identification of brain metastases in metastatic renal cell carcinoma (mRCC), , Journal of Clinical Oncology, 2020
  • Impact of PSMA-targeted imaging with 18F-DCFPyL-PET/CT on clinical management of patients (pts) with biochemically recurrent (BCR) prostate cancer (PCa): Results from a phase III, prospective, multicenter study (CONDOR), , Journal of Clinical Oncology, 2020
  • Neutrophil-to-lymphocyte Ratio as a Predictive Marker of Response to Abiraterone Acetate: A Retrospective Analysis of the COU302 Study., , European urology oncology., 2020, 10.1016/j.euo.2019.01.009
  • Outcomes of complete metastasectomy in metastatic renal cell carcinoma patients: The Canadian Kidney Cancer information system experience., , Urologic oncology, 2020, 10.1016/j.urolonc.2020.07.021
  • OUTCOMES OF RADIOTHERAPY PLUS IMMUNOTHERAPY IN METASTATIC RENAL CELL CARCINOMA: RESULTS FROM THE CANADIAN KIDNEY CANCER INFORMATION SYSTEM (CKCis), , Radiotherapy and Oncology, 2020
  • Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426, , Journal of Clinical Oncology, 2020
  • Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial., , The Lancet. Oncology, 2020, 10.1016/S1470-2045(20)30436-8
  • Real-world evidence of cabozantinib in metastatic renal-cell carcinoma (mRCC): Results from the Canadian Kidney Cancer Information System (CKCis), , Journal of Clinical Oncology, 2020
  • Real-world management of advanced prostate cancer: A Canadian comparison of academic specialists and community-based prostate cancer physicians, , Journal of Clinical Oncology, 2020
  • Real-world utilization and safety of ipilimumab plus nivolumab (I plus N) in metastatic renal cell carcinoma (mRCC) patients: Results from the Canadian Kidney Cancer Information System (CKCis), , Journal of Clinical Oncology, 2020
  • Testosterone Breakthrough Rates during Androgen Deprivation Therapy for Castration Sensitive Prostate Cancer., , The Journal of urology, 2020, 10.1097/JU.0000000000000809
  • 2019 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC)., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2019, 10.5489/cuaj.6136
  • A PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF (TC)-T-99M-MIP-1404 SPECT/CT IMAGING TO DETECT CLINICALLY SIGNIFICANT PROSTATE CANCER IN MEN WITH BIOPSY PROVEN LOW GRADE PROSTATE CANCER WHO ARE CANDIDATES FOR ACTIVE SURVEILLANCE (PROSPECT-AS), , Journal of Urology, 2019
  • A phase Ill, multicenter study to assess the diagnostic performance and clinical impact of F-18-DCFPyL PET/CT in men with suspected recurrence of prostate cancer (CONDOR), , Journal of Clinical Oncology, 2019, 10.1200/JCO.2019.37.15_suppl.TPS5093
  • A PROSPECTIVE PHASE 2/3 MULTI-CENTER STUDY OF F-18-DCFPYL PET/CT IMAGING IN PATIENTS WITH PROSTATE CANCERe EXAMINATION OF DIAGNOSTIC ACCURACY (OSPREY), , Journal of Urology, 2019
  • Active surveillance in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis), , Journal of Clinical Oncology, 2019, 10.1200/JCO.2019.37.15_suppl.4516
  • AUTHOR INDEX, , Asia-Pacific Journal of Clinical Oncology, 2019, 10.1111/ajco.13229
  • Cancer-associated fibroblasts induce epithelial-mesenchymal transition of bladder cancer cells through paracrine IL-6 signalling., , BMC cancer, 2019, 10.1186/s12885-019-5353-6
  • Charlson Comorbidity Index as a Predictor of Cancer Mortality Beyond 10 Years after Radical Prostatectomy, , Clinics in oncology., 2019
  • Development and Implementation of a Continuing Medical Education Program in Canada: Knowledge Translation for Renal Cell Carcinoma (KT4RCC)., , Journal of cancer education : the official journal of the American Association for Cancer Education, 2019, 10.1007/s13187-017-1259-7
  • Development of a Transcriptional Amplification System Based on the PEG3 Promoter to Target Androgen Receptor-Positive and -Negative Prostate Cancer Cells., , International journal of molecular sciences, 2019, 10.3390/ijms20010216
  • Diabetes and kidney cancer survival in patients undergoing nephrectomy: A Canadian multi-center, propensity score analysis., , Urologic oncology, 2019, 10.1016/j.urolonc.2019.06.006
  • Diagnostic performance of F-18-DCFPyL in the OSPREY Trial: A prospective phase 2/3 multicenter study of F-18-DCFPyL PET/CT imaging in patients (Pts) with known or suspected metastatic prostate cancer (mPC), , Journal of Clinical Oncology, 2019, 10.1200/JCO.2019.37.15_suppl.5012
  • Discordance between testosterone measurement methods in castrated prostate cancer patients., , Endocrine connections., 2019, 10.1530/EC-18-0476
  • First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC): Results from KEYNOTE-427 cohort B, , Journal of Clinical Oncology, 2019, 10.1200/JCO.2019.37.7_suppl.546
  • First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated results for KEYNOTE-427 cohort A, , Journal of Clinical Oncology, 2019, 10.1200/JCO.2019.37.15_suppl.4570
  • IMPACT OF TIME-TO-SURGERY AND SURGICAL DELAY ON ONCOLOGIC OUTCOMES FOR RENAL CELL CARCINOMA, , Journal of Urology, 2019
  • Increased Prostate Cancer Glucose Metabolism Detected by 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Localised Gleason 8-10 Prostate Cancers Identifies Very High-risk Patients for Early Recurrence and Resistance to Castration., , European urology focus, 2019, 10.1016/j.euf.2018.03.008
  • KEYNOTE-427 cohort B: First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (NCC-RCC), , Journal of Clinical Oncology, 2019, 10.1200/JCO.2019.37.15_suppl.4569
  • Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of renal mass biopsy in the management of kidney cancer., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2019, 10.5489/cuaj.6176
  • Morphologic subtyping as a prognostic predictor for survival in papillary renal cell carcinoma: Type 1 vs. type 2., , Urologic oncology, 2019, 10.1016/j.urolonc.2019.05.009
  • ONCOLOGICAL OUTCOMES OF PATIENTS WITH SPORADIC, NON-METASTATIC RENAL CELL CARCINOMA WITH RENAL VEIN OR INFERIOR VENA CAVA TUMOR THROMBUS, , Journal of Urology, 2019
  • Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for locally advanced or metastatic renal cell carcinoma (mRCC): phase Ill KEYNOTE-426 study, , Journal of Clinical Oncology, 2019, 10.1200/JCO.2019.37.7_suppl.543
  • Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study, , Journal of Clinical Oncology, 2019, 10.1200/JCO.2019.37.15_suppl.4500
  • Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma., , The New England journal of medicine, 2019, 10.1056/NEJMoa1816714
  • Plasma extracellular vesicles as phenotypic biomarkers in prostate cancer patients., , The Prostate, 2019, 10.1002/pros.23901
  • Prospective, Multisite, International Comparison of F-Fluoromethylcholine PET/CT, Multiparametric MRI, and Ga-HBED-CC PSMA-11 PET/CT in Men with High-Risk Features and Biochemical Failure After Radical Prostatectomy: Clinical Performance and Patient Outcomes., , Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2019, 10.2967/jnumed.118.220103
  • RENAL BIOPSY - WHEN WILL IT CHANGE MANAGEMENT?, , Journal of Urology, 2019
  • Renal cell carcinoma in the Canadian Indigenous population., , Current oncology (Toronto, Ont.), 2019, 10.3747/co.26.4707
  • Renal hypothermia during partial nephrectomy for patients with renal tumours: a randomised controlled clinical trial protocol., , BMJ open, 2019, 10.1136/bmjopen-2018-025662
  • Results from the OSPREY trial A PrOspective Phase 2/3 Multi-Center Study of F-18-DCFPyL, PET/CT Imaging in Patients with PRostate Cancer - Examination of Diagnostic AccuracY, , Journal of Nuclear Medicine, 2019
  • The contribution of multiparametric pelvic and whole body MR to the interpretation of F-18-fluoromethylcholine(FCH) or Ga-68-HBED-CC PSMA-11 (PSMA) PET/CT in the detection of pelvic recurrence or distant metastases in patients with biochemical failure following radical prostatectomy, , Journal of Nuclear Medicine, 2019
  • The Contribution of Multiparametric Pelvic and Whole-Body MRI to Interpretation of F-Fluoromethylcholine or Ga-HBED-CC PSMA-11 PET/CT in Patients with Biochemical Failure After Radical Prostatectomy., , Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2019, 10.2967/jnumed.118.225185
  • Validation of Ga-68 -Ga-DOTA-TATE using Ga-68 produced by cyclotron, , Journal of Nuclear Medicine, 2019
  • Validation of Ga-68-4HMSA-PSMA, a novel PSMA radioligand for PET Imaging of Prostate Cancer, , Journal of Nuclear Medicine, 2019
  • A LATS biosensor screen identifies VEGFR as a regulator of the Hippo pathway in angiogenesis., , Nature communications, 2018, 10.1038/s41467-018-03278-w
  • A PROSPECTIVE MULTICENTER STUDY COMPARING MULTI-PARAMETRIC MAGNETIC RESONANCE IMAGING (MP-MRI), F-18 FLUORO-METHYL-CHOLINE (FCH) AND GA-68 HBED-CC-(PSMA) POSITRON EMISSION TOMOGRAPHY IN PATIENTS BEING CONSIDERED FOR SALVAGE RADIATION THERAPY FOR BIOCHEMICAL FAILURE AFTER RADICAL PROSTATECTOMY, , Journal of Urology, 2018
  • A prospective phase 2/3 multicenter study of F-18-DCFPyL PET/CT imaging in patients with prostate cancer: Examination of diagnostic accuracy (OSPREY), , Journal of Clinical Oncology, 2018, 10.1200/JCO.2018.36.15_suppl.TPS5092
  • A prospective, multinational comparison of multi-parametric and whole body magnetic resonance imaging (mp-MRI and WB-MRI) F-18 fluoro-methyl-choline (FCH) and Ga-68 HBED-CC-(PSMA) in high risk men being considered for salvage radiation treatment for biochemical failure post radical prostatectomy: Detection rates, management impact and treatment response, , Journal of Nuclear Medicine, 2018
  • Application of Canadian hereditary renal cell carcinoma risk criteria to a population database, , Journal of Clinical Oncology, 2018, 10.1200/JCO.2018.36.6_suppl.621
  • Canadian Urological Association guideline for followup of patients after treatment of non-metastatic renal cell carcinoma., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2018, 10.5489/cuaj.5462
  • DO HIGH-VOLUME RENAL TUMOR BIOPSY CENTERS HAVE LOWER RATES OF BENIGN HISTOLOGY FOLLOWING NEPHRECTOMY FOR SMALL RENAL MASSES?, , Journal of Urology, 2018
  • Exosomes Induce Fibroblast Differentiation into Cancer-Associated Fibroblasts through TGFβ Signaling., , Molecular cancer research : MCR, 2018, 10.1158/1541-7786.MCR-17-0784
  • Is Routine Renal Tumor Biopsy Associated with Lower Rates of Benign Histology following Nephrectomy for Small Renal Masses?, , The Journal of urology, 2018, 10.1016/j.juro.2018.04.015
  • Kidney Cancer Research Network of Canada consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: A comprehensive analysis of the literature and meta-analysis of randomized controlled trials., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2018, 10.5489/cuaj.5187
  • Modeling human bladder cancer., , World journal of urology, 2018, 10.1007/s00345-018-2369-5
  • Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): Results from cohort A of KEYNOTE-427, , Journal of Clinical Oncology, 2018, 10.1200/JCO.2018.36.15_suppl.4500
  • PREDICTORS OF PATHOLOGICALLY NODE POSITIVE DISEASE IN PATIENTS UNDERGOING RETROPERITONEAL LYMPH NODE DISSECTION (RPLND) FOR RENAL CELL CARCINOMA (RCC): RESULTS FROM THE CANADIAN KIDNEY CANCER COLLABORATION, , Journal of Urology, 2018
  • Prognostic value of urinary prostate cancer antigen 3 (PCA3) during active surveillance of patients with low-risk prostate cancer receiving 5α-reductase inhibitors., , BJU international, 2018, 10.1111/bju.14041
  • Prostate-specific membrane antigen for prostate cancer theranostics: from imaging to targeted therapy., , Current opinion in supportive and palliative care, 2018, 10.1097/SPC.0000000000000357
  • Serum Sex Steroids as Prognostic Biomarkers in Patients Receiving Androgen Deprivation Therapy for Recurrent Prostate Cancer: A Analysis of the PR.7 Trial., , Clinical cancer research : an official journal of the American Association for Cancer Research, 2018, 10.1158/1078-0432.CCR-18-1187
  • Serum sex steroids as prognostic biomarkers in patients receiving androgen-deprivation therapy for recurrent prostate cancer post-radiotherapy: A post hoc analysis of the PR.7 trial, , Cancer Research, 2018, 10.1158/1538-7445.Prca2017-a072
  • Symptom assessment to guide treatment selection and determine progression in metastatic castration-resistant prostate cancer: Expert opinion and review of the evidence., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2018, 10.5489/cuaj.5154
  • 3D tissue engineering bladder model for cancer invasion study, , Cancer Research, 2017, 10.1158/1538-7445.Am2017-5791
  • A Multicentered, Propensity Matched Analysis Comparing Laparoscopic and Open Surgery for pT3a Renal Cell Carcinoma., , Journal of endourology, 2017, 10.1089/end.2016.0787
  • Benchmarking quality for renal cancer surgery: Canadian Kidney Cancer information system (CKCis) perspective., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2017, 10.5489/cuaj.4397
  • CUA guideline on the management of cystic renal lesions., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2017, 10.5489/cuaj.4484
  • Follow-up imaging after nephrectomy for cancer in Canada: urologists' compliance with guidelines. An observational study., , CMAJ open, 2017, 10.9778/cmajo.20170005
  • Investigation of the In Vitro and In Vivo efficiency of RM-532-105, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, in LAPC-4 prostate cancer cell and tumor models., , PloS one, 2017, 10.1371/journal.pone.0171871
  • Maximal testosterone suppression in the management of recurrent and metastatic prostate cancer., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2017, 10.5489/cuaj.4303
  • Metabolic Imaging of Prostate Cancer Reveals Intrapatient Intermetastasis Response Heterogeneity to Systemic Therapy., , European urology focus, 2017, 10.1016/j.euf.2017.02.007
  • New research in kidney cancer, ASCO-GU 2017., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2017, 10.5489/cuaj.4607
  • Proteomic identification of therapeutics targets for Enzalutamide resistance in Castration Resistant Prostate Cancer, , Cancer Research, 2017, 10.1158/1538-7445.Am2017-220
  • Safety, reliability and accuracy of small renal tumour biopsies: results from a multi-institution registry., , BJU international, 2017, 10.1111/bju.13630
  • Supplementary data: Maximal testosterone suppression in the management of recurrent and metastatic prostate cancer., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2017, 10.5489/cuaj.4494
  • Testosterone monitoring for men with advanced prostate cancer: Review of current practices and a survey of Canadian physicians., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2017, 10.5489/cuaj.4539
  • Tissue-engineered human 3D model of bladder cancer for invasion study and drug discovery., , Biomaterials, 2017, 10.1016/j.biomaterials.2017.08.041
  • A PCA3 gene-based transcriptional amplification system targeting primary prostate cancer., , Oncotarget, 2016, 10.18632/oncotarget.6360
  • Bioluminescence Microscopy as a Method to Measure Single Cell Androgen Receptor Activity Heterogeneous Responses to Antiandrogens., , Scientific reports, 2016, 10.1038/srep33968
  • Corrigendum: Bioluminescence Microscopy as a Method to Measure Single Cell Androgen Receptor Activity Heterogeneous Responses to Antiandrogens., , Scientific reports, 2016, 10.1038/srep37381
  • Development of a multigenic bioluminescence imaging system to detect prostate cancer cells and assess their response to therapy, , Cancer Research, 2016, 10.1158/1538-7445.Am2016-4764
  • Phase II Drug-Metabolizing Polymorphisms and Smoking Predict Recurrence of Non-Muscle-Invasive Bladder Cancer: A Gene-Smoking Interaction., , Cancer prevention research (Philadelphia, Pa.), 2016, 10.1158/1940-6207.CAPR-15-0069
  • Renal cell carcinoma with thrombus extending to the hepatic veins or right atrium: operative strategies based on 41 consecutive patients., , European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 2016, 10.1093/ejcts/ezw023
  • Are warm ischemia and ischemia time still predictive factors of poor renal function after partial nephrectomy in the setting of elective indication?, , World journal of urology, 2015, 10.1007/s00345-014-1292-7
  • CSF1 receptor targeting in prostate cancer reverses macrophage-mediated resistance to androgen blockade therapy., , Cancer research, 2015, 10.1158/0008-5472.CAN-14-0992
  • Development of a molecular imaging system based on the transcriptional activity of the DD3/PCA3 non-coding RNA for imaging specifically the prostate cancer cells, , Cancer Research, 2015, 10.1158/1538-7445.Am2015-206
  • DEVELOPMENT OF A MOLECULAR IMAGING SYSTEM BASED ON THE TRANSCRIPTIONAL ACTIVITY OF THE DD3/PCA3 NON-CODING RNA FOR IMAGING SPECIFICALLY THE PROSTATE CANCER CELLS, , Journal of Urology, 2015, 10.1016/j.juro.2015.02.2194
  • FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy., , Cancer imaging : the official publication of the International Cancer Imaging Society, 2015, 10.1186/s40644-015-0038-0
  • New developments in the imaging of metastatic prostate cancer., , Current opinion in supportive and palliative care, 2014, 10.1097/SPC.0000000000000076
  • A molecular imaging system based on both transcriptional and genomic amplification to detect prostate cancer cells in vivo., , Molecular therapy : the journal of the American Society of Gene Therapy, 2013, 10.1038/mt.2012.259
  • DETERMINATION OF THE ACCURACY OF FDG-PET/CT IN THE PRIMARY STAGING OF BIOLOGICAL HIGH RISK PROSTATE CANCERS BEFORE LOCAL THERAPIES: INCREASED UPTAKE ASSOCIATED WITH HIGHLY AGGRESSIVE TUMORS, , Journal of Urology, 2013, 10.1016/j.juro.2013.02.1621
  • GLUT-1, GLUT-12 AND HK2 PROTEIN EXPRESSION IN PROSTATIC ADENOCARNINOMA: CLINICAL CORRELATION WITH INTRAPROSTATIC 18F-FDG-POSITRON EMISSION TOMOGRAPHY (FDG-PET) UPTAKE, , Journal of Urology, 2013, 10.1016/j.juro.2013.02.2108
  • Salvage-targeted kidney cancer therapy in patients progressing on high-dose interleukin-2 immunotherapy: the UCLA experience., , Cancer journal (Sudbury, Mass.), 2013, 10.1097/PPO.0b013e318292e8a4
  • ANTITUMOR ACTIVITY OF SUNITINIB VERSUS OTHER FDA-APPROVED TARGETED CANCER AGENTS AGAINST METASTATIC RENAL CELL CARCINOMA IN THE FIRST-LINE SETTING, , Journal of Urology, 2012, 10.1016/j.juro.2012.02.2165
  • Non-clear cell histology in patients with metastatic RCC as a prognostic indicator in the targeted therapy era, , Journal of Clinical Oncology, 2012, 10.1200/jco.2012.30.5_suppl.454
  • NON-CLEAR CELL HISTOLOGY IS INDEPENDENTLY ASSOCIATED WITH POOR OUTCOMES IN THE TARGETED THERAPY ERA, , Journal of Urology, 2012, 10.1016/j.juro.2012.02.2164
  • Prospective study comparing two techniques of renal clamping in laparoscopic partial nephrectomy: impact on perioperative parameters., , Journal of endourology, 2012, 10.1089/end.2011.0088
  • UISS RISK STRATIFICATION CAN IDENTIFY PATIENTS LESS LIKELY TO BENEFIT FROM CYTOREDUCTIVE NEPHRECTOMY IN THE TARGETED THERAPY ERA, , Journal of Urology, 2012, 10.1016/j.juro.2012.02.1079
  • CANCER-SPECIFIC SURVIVAL OUTCOMES OF SUNITINIB TREATMENT IN UISS RISK-STRATIFIED METASTATIC RCC PATIENTS, , Journal of Urology, 2011, 10.1016/j.juro.2011.02.2098
  • Cardiopulmonary bypass and renal cell carcinoma with level IV tumour thrombus: can deep hypothermic circulatory arrest limit perioperative mortality?, , BJU international, 2011, 10.1111/j.1464-410X.2010.09488.x
  • Dietary omega-3 fatty acids, genetic variation and risk of breast and prostate cancers., , World review of nutrition and dietetics, 2011, 10.1159/000327805
  • Immunological therapy in urological malignancy: novel combination strategies., , International journal of urology : official journal of the Japanese Urological Association, 2011, 10.1111/j.1442-2042.2010.02664.x
  • Multivariate analysis of the factors involved in loss of renal differential function after laparoscopic partial nephrectomy: a role for warm ischemia time., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2011, 10.5489/cuaj.10044
  • Quality of pathological reporting for renal cell cancer: implications for systemic therapy, prognostication and surveillance., , BJU international, 2011, 10.1111/j.1464-410X.2010.09871.x
  • ROBOTIC VS LAPAROSCOPIC PYELOPLASTY: A TWO-CENTER INTERNATIONAL STUDY WITH LONG TERM SCINTIGRAPHIC FOLLOW-UP, , Journal of Urology, 2011, 10.1016/j.juro.2011.02.1815
  • A DUAL ADENOVIRAL AMPLIFICATION SYSTEM BASED ON PSA-PROMOTER TO INCREASE SENSITIVITY OF DETECTION OF PROSTATE CANCER CELLS IN VIVO BY NON INVASIVE IMAGING, , Journal of Urology, 2010, 10.1016/j.juro.2010.02.2254
  • Cardiac glycosides may affect prostate specific antigen levels., , The Journal of urology, 2010, 10.1016/j.juro.2010.08.052
  • Contemporary management of renal tumors with venous tumor thrombus., , The Journal of urology, 2010, 10.1016/j.juro.2010.04.071
  • Determination of success by objective scintigraphic criteria after laparoscopic pyeloplasty., , Journal of endourology, 2010, 10.1089/end.2009.0134
  • Histologic evaluation of metastases in renal cell carcinoma with sarcomatoid transformation and its implications for systemic therapy., , Cancer, 2010, 10.1002/cncr.24768
  • Primary and salvage cryotherapy for prostate cancer., , The Urologic clinics of North America, 2010, 10.1016/j.ucl.2009.11.007
  • VALIDATION OF CA-IX POLYMORPHISM RS12553173 AS AN INDEPENDENT PROGNOSTIC FACTOR OF OVERALL SURVIVAL IN METASTATIC CLEAR CELL RENAL CELL CARCINOMA, , Journal of Urology, 2010, 10.1016/j.juro.2010.02.1716
  • COMPARISON OF OPEN VERSUS LAPAROSCOPIC PARTIAL NEPHRECTOMY: AVOIDING SELECTION BIAS BY MATCHED ANALYSIS, , Journal of Urology, 2009, 10.1016/s0022-5347(09)61330-6
  • EARLY POST-OPERATIVE RENAL SCINTIGRAPHY AS A PREDICTOR OF LONG TERM OUTCOMES AFTER LAPAROSCOPIC PYELOPLASTIES, , Journal of Urology, 2009, 10.1016/s0022-5347(09)61321-5
  • EARLY RENAL FUNCTION OUTCOMES FOLLOWING OPEN VS LAPAROSCOPIC PARTIAL NEPHRECTOMY: HOW DO THEY COMPARE?, , Journal of Urology, 2009, 10.1016/s0022-5347(09)60997-6
  • EFFECT OF WARM ISCHEMIA TIME ON RENAL DIFFERENTIAL RENAL FUNCTION AFTER RENAL ARTERY CLAMPING FOR LAPAROSCOPIC PARTIAL NEPHRECTOMY, , Journal of Urology, 2009, 10.1016/s0022-5347(09)60787-4
  • In Vivo Detection of Prostate Cancer Cells by a PSA-Promoter Dependent Reporter Adenovirus: A Model To Image Local Recurrence after Radical Prostatectomy, , Molecular Therapy, 2009
  • PROSPECTIVE STUDY COMPARING TWO TECHNIQUES OF CLAMPING IN LAPAROSCOPIC PARTIAL NEPHRECTOMY: IMPACT ON PERIOPERATIVE PARAMETERS, , Journal of Urology, 2009, 10.1016/s0022-5347(09)61340-9
  • Comparative analysis of scintigraphic and clinical criteria to determine success after laparoscopic pyeloplasties, , Journal of Urology, 2008, 10.1016/s0022-5347(08)60828-9
  • Comparative analysis of transperitoneal and retroperitoneal laparoscopic partial nephrectomies: Laval University experience, , Journal of Endourology, 2006
  • Chylous ascites as a complication of laparoscopic donor nephrectomy., , Transplant international : official journal of the European Society for Organ Transplantation, 2005, 10.1111/j.1432-2277.2005.00219.x
  • Expression profile of agonistic Smads in human breast cancer cells: absence of regulation by estrogens., , International journal of cancer, 1999, 10.1002/(sici)1097-0215(19990331)81:13.0.co;2-9
  • Effect of dehydroepiandrosterone and the antiestrogen EM-800 on growth of human ZR-75-1 breast cancer xenografts., , Journal of the National Cancer Institute, 1998, 10.1093/jnci/90.10.772
  • Structure of the gene encoding the human cyclin-dependent kinase inhibitor p18 and mutational analysis in breast cancer., , Biochemical and biophysical research communications, 1998, 10.1006/bbrc.1998.8497
  • 3D TISSUE ENGINEERING BLADDER MODEL FOR CANCER INVASION STUDY, , Journal of Urology, 1911

Contribution à l'enseignement aux cycles supérieurs

Étudiant(e)s dirigé(e)s*

Depuis 2009
  • Samuel Tremblay - Maitrîse avec mémoire - En cours
  • Imen Chebra - Doctorat - En cours
  • Sébastien Le Batteux - Doctorat - En cours
  • Steven Lagacé - Maitrîse avec mémoire - En cours
  • Nawar Touma - Maitrîse avec mémoire - En cours
  • Pallavi Jain - Doctorat - 2017/01
  • Lauriane Vélot - Doctorat - 2018/09
  • Cassandra Ringuette Goulet - Doctorat - 2019/01
  • Audrey Champagne - Doctorat - 2021/05
  • Danahé LeBlanc - Maitrîse avec mémoire - 2021/09
*Les supervisions d’étudiant(e)s de 1er cycle en stage de recherche et de résident(e)s aux études médicales postdoctorales seront répertoriées ultérieurement.

Direction et personnes-ressources

Vice-décanat à la recherche et aux études supérieures
Pavillon Ferdinand-Vandry
Université Laval
1050, avenue de la Médecine, local 4645
Québec (Québec) G1V 0A6
Canada

Renseignements - Secrétariat
418 656-2690
vdres@fmed.ulaval.ca

Jacques Simard
Vice-doyen à la recherche et aux études supérieures
vice-doyen.recherche-et-etudes-superieures@fmed.ulaval.ca

Louise Laperrière
Adjointe au vice-doyen à la recherche et aux études supérieures
louise.laperriere@fmed.ulaval.ca 

Volet recherche
Gestion financière
Volet études aux cycles supérieurs